NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
复制标题
DOI:
10.1097/pas.0000000000001055
复制
发表时间:
2018-06
期刊:
影响因子:
--
通讯作者:
Antonescu CR
中科院分区:
文献类型:
--
作者:
Chiang S;Cotzia P;Hyman DM;Drilon A;Tap WD;Zhang L;Hechtman JF;Frosina D;Jungbluth AA;Murali R;Park KJ;Soslow RA;Oliva E;Iafrate AJ;Benayed R;Ladanyi M;Antonescu CR
Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified four NTRK fusion-positive uterine sarcomas that should be distinguished from leiomyosarcoma and undifferentiated uterine sarcoma. NTRK rearrangements were detected by fluorescence in situ hybridization (FISH) and/or targeted RNA or DNA sequencing in four undifferentiated uterine sarcomas with spindle cell morphology. Due to histologic overlap with leiomyosarcoma, TrkA and pan-Trk immunohistochemistry was performed in 97 uterine leiomyosarcomas. NTRK1 and NTRK3 FISH was performed on tumors with TrkA or pan-Trk staining. We also performed whole transcriptome RNA sequencing of a leiomyosarcoma with TrkA expression, and targeted RNA sequencing of two additional undifferentiated uterine sarcomas. FISH and/or targeted RNA or DNA sequencing in the study group showed TPM3-NTRK1, LMNA-NTRK1, RBPMS-NTRK3, and TPR-NTRK1 fusions. All tumors were composed of fascicles of spindle cells. Mitotic index was 7-30 mitotic figures per 10 high power fields; tumor necrosis was seen in two tumors. Desmin, estrogen receptor and progesterone receptor were negative in all tumors, while pan-Trk was expressed in all tumors with concurrent TrkA staining in three of them. TrkA and/or pan-Trk staining was also seen six leiomyosarcomas, but these tumors lacked NTRK fusions or alternative isoforms by FISH or whole transcriptome sequencing. No fusions were detected in two undifferentiated uterine sarcomas. NTRK fusion-positive uterine spindle cell sarcomas constitute a novel tumor type with features of fibrosarcoma; patients with these tumors may benefit from Trk inhibition. TrkA and pan-Trk expression in leiomyosarcomas is rare and does not correlate with NTRK rearrangement.